Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) have been assigned a consensus rating of “Moderate Buy” from the five research firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $41.00.

Several equities analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th.

Insider Activity

In related news, COO Anish Patel sold 48,300 shares of the stock in a transaction on Friday, January 9th. The stock was sold at an average price of $27.99, for a total value of $1,351,917.00. Following the transaction, the chief operating officer owned 215,011 shares of the company’s stock, valued at $6,018,157.89. This represents a 18.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Richard A. Heyman sold 9,635 shares of Enliven Therapeutics stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $25.03, for a total value of $241,164.05. Following the sale, the director directly owned 25,545 shares of the company’s stock, valued at $639,391.35. This trade represents a 27.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 259,280 shares of company stock worth $6,635,968. 25.90% of the stock is currently owned by company insiders.

Institutional Trading of Enliven Therapeutics

Institutional investors have recently modified their holdings of the stock. Affinity Asset Advisors LLC acquired a new position in Enliven Therapeutics during the second quarter worth approximately $8,024,000. Geode Capital Management LLC grew its position in Enliven Therapeutics by 7.8% during the 2nd quarter. Geode Capital Management LLC now owns 882,753 shares of the company’s stock worth $17,711,000 after purchasing an additional 63,580 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of Enliven Therapeutics by 2,029.3% during the second quarter. Franklin Resources Inc. now owns 430,240 shares of the company’s stock worth $8,631,000 after buying an additional 410,034 shares during the last quarter. KLP Kapitalforvaltning AS grew its position in Enliven Therapeutics by 58.1% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock valued at $136,000 after buying an additional 2,500 shares during the last quarter. Finally, SG Americas Securities LLC grew its stake in shares of Enliven Therapeutics by 177.4% during the 2nd quarter. SG Americas Securities LLC now owns 36,373 shares of the company’s stock worth $730,000 after purchasing an additional 23,261 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Stock Up 6.5%

Shares of ELVN opened at $28.17 on Tuesday. The company has a market cap of $1.67 billion, a P/E ratio of -15.31 and a beta of 0.34. Enliven Therapeutics has a fifty-two week low of $13.30 and a fifty-two week high of $29.98. The firm’s 50 day moving average price is $20.96 and its 200 day moving average price is $20.52.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.11. Research analysts forecast that Enliven Therapeutics will post -1.95 earnings per share for the current year.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.